Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection
Purpose Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our knowledge, pazopanib exposure in patients with gastrointestinal resections (GIR) has not been described. This report focuses on feasibility of pharmacokinetics-guided dose escalation in these patients and clinical implications for their management. Method A retrospective data collection was performed for three patients with GIR treated with pazopanib, including pazopanib plasma concentrations (high-performance liquid chromatography with UV detection) and treatment adherence (Girerd score). Case presentation First patient (55-year-old man, RCC, gastric bypass surgery) pazopanib Cmin,ss at day 39 was 4.1 mg/L. Dose escalation to 1800 mg/day fractionated allowed to reach Cmin,ss of 18.5 mg/L (target threshold in RCC patients: 20.5 mg/L). Patient 2 (50-year-old woman, metastatic myxofibrosarcoma, gastric band) showed Cmin,ss of 4.0 mg/L at day 13. In patient 3 (49-year-old man, gastric malignant peripheral nerve sheath tumor, gastrectomy), Cmin,ss at day 13 was 2.7 mg/L. For these two patients, intake with food and dose fractioning only slightly increased pazopanib Cmin,ss to 12.0 mg/L and 6.5 mg/L, respectively (therapeutic threshold in sarcoma patients: 27 mg/L). Treatment adherence was good in all patients. Conclusion Optimal pazopanib exposure cannot be achieved in patients with GIR, and thus, other therapeutic strategies should be encouraged. Pretherapeutic assessment seems crucial to evaluate factors as bariatric surgery that may impact pazopanib concentrations. Therapeutic drug monitoring could be helpful to optimize pazopanib response in these patients..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
Cancer chemotherapy and pharmacology - 93(2023), 2 vom: 24. Aug., Seite 169-175 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tardy, Cléa [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Dose escalation |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023 |
---|
doi: |
10.1007/s00280-023-04574-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR054687667 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR054687667 | ||
003 | DE-627 | ||
005 | 20240209064639.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240209s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00280-023-04574-z |2 doi | |
035 | |a (DE-627)SPR054687667 | ||
035 | |a (SPR)s00280-023-04574-z-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tardy, Cléa |e verfasserin |0 (orcid)0009-0008-3727-946X |4 aut | |
245 | 1 | 0 | |a Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023 | ||
520 | |a Purpose Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our knowledge, pazopanib exposure in patients with gastrointestinal resections (GIR) has not been described. This report focuses on feasibility of pharmacokinetics-guided dose escalation in these patients and clinical implications for their management. Method A retrospective data collection was performed for three patients with GIR treated with pazopanib, including pazopanib plasma concentrations (high-performance liquid chromatography with UV detection) and treatment adherence (Girerd score). Case presentation First patient (55-year-old man, RCC, gastric bypass surgery) pazopanib Cmin,ss at day 39 was 4.1 mg/L. Dose escalation to 1800 mg/day fractionated allowed to reach Cmin,ss of 18.5 mg/L (target threshold in RCC patients: 20.5 mg/L). Patient 2 (50-year-old woman, metastatic myxofibrosarcoma, gastric band) showed Cmin,ss of 4.0 mg/L at day 13. In patient 3 (49-year-old man, gastric malignant peripheral nerve sheath tumor, gastrectomy), Cmin,ss at day 13 was 2.7 mg/L. For these two patients, intake with food and dose fractioning only slightly increased pazopanib Cmin,ss to 12.0 mg/L and 6.5 mg/L, respectively (therapeutic threshold in sarcoma patients: 27 mg/L). Treatment adherence was good in all patients. Conclusion Optimal pazopanib exposure cannot be achieved in patients with GIR, and thus, other therapeutic strategies should be encouraged. Pretherapeutic assessment seems crucial to evaluate factors as bariatric surgery that may impact pazopanib concentrations. Therapeutic drug monitoring could be helpful to optimize pazopanib response in these patients. | ||
650 | 4 | |a Pazopanib |7 (dpeaa)DE-He213 | |
650 | 4 | |a Therapeutic drug monitoring |7 (dpeaa)DE-He213 | |
650 | 4 | |a Gastrointestinal resections |7 (dpeaa)DE-He213 | |
650 | 4 | |a Dose escalation |7 (dpeaa)DE-He213 | |
700 | 1 | |a Puszkiel, Alicja |4 aut | |
700 | 1 | |a Boudou-Rouquette, Pascaline |4 aut | |
700 | 1 | |a De Percin, Sixtine |4 aut | |
700 | 1 | |a Alexandre, Jérôme |4 aut | |
700 | 1 | |a Berge, Marion |4 aut | |
700 | 1 | |a Ulmann, Guillaume |4 aut | |
700 | 1 | |a Blanchet, Benoit |4 aut | |
700 | 1 | |a Batista, Rui |4 aut | |
700 | 1 | |a Goldwasser, Francois |4 aut | |
700 | 1 | |a Thomas Schoemann, Audrey |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d Berlin : Springer, 1978 |g 93(2023), 2 vom: 24. Aug., Seite 169-175 |w (DE-627)SPR003577996 |w (DE-600)1458488-8 |x 1432-0843 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2023 |g number:2 |g day:24 |g month:08 |g pages:169-175 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00280-023-04574-z |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 93 |j 2023 |e 2 |b 24 |c 08 |h 169-175 |